ArticlePloS one2026
Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetically determined ABO blood group, secretor status, Lewis antigens, and panNEN risk.Endocrine-related cancer · 2026Article
- Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models.NPJ precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) remains a highly fatal malignancy due partly to treatment resistance in many patients. We previously identified a functional germline deletion overlapping exon 6 of CTRB2 (CTRB2ex6) at a PDAC genome-wide risk locus on chr16q23.1. This variant leads to a nonfunctional truncated chymotrypsin protein that accumulates intracellularly and induces endoplasmic reticulum stress. Here, we performed a retrospective study to determine whether CTRB2ex6 deletions are associated with response to chemotherapy, time to cancer progression, or overall survival (OS) in PDAC patients.
methodsThe study included CTRB2 genotype data from two independent PDAC cohorts (Cohort 1: n = 633; Cohort 2: n = 3,896). We examined associations between CTRB2ex6 deletion status and OS and time-to-progression (TTP) using Cox proportional hazard modeling. TTP was also evaluated in a subset of chemotherapy-treated patients in Cohort 1 (n = 263) to determine the impact of CTRB2ex6 deletion status on chemotherapy response.
resultsCTRB2ex6 deletions were found in 20% of patients in both cohorts combined (19% in Cohort 1, and 21% in Cohort 2). No significant difference was observed in OS by CTRB2 deletion status in either cohort (Cohort 1: HR = 0.95, p = 0.60; Cohort 2: HR = 1.04, p = 0.43). Among chemotherapy-treated patients in Cohort 1, CTRB2 deletion carriers had a longer median TTP (20.4 vs. 12 months), though this was not statistically significant (p = 0.49). Homozygous deletion carriers had the longest TTP (70 months). DISCUSSION: No clinical impact on chemotherapy response or OS was observed by CTRB2 deletion status. Further studies are needed to identify reliable biomarkers of therapy response in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.